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Summary
Diffuse large B-cell lymphoma (DLBCL) is the most
frequently-occurring type of malignant lymphoma in the
Western world. It has an aggressive natural history, with a
median survival of less than one year if left untreated. Im-
munochemotherapy regimens, consisting of the anti-CD20
antibody rituximab typically in combination with cyclo-
phosphamide, doxorubicin, vincristine and prednisone
(CHOP), are currently the treatment backbone. Despite re-
markable progress in improving patient survival, clinical
outcomes are still unsatisfactory for certain subsets of pa-
tients, including the elderly and very elderly and those with
highly aggressive disease. This review outlines some of the
current treatment strategies for DLBCL and discusses the
main issues that affect clinical practice.
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Abbreviations
aaIPI = age-adjusted International Prognostic Index; ABC
= activated B-cell – like; ACVBP = doxorubicin, cyc-
lophosphamide, vincristine, bleomycin and prednisone;
ASCO = American Society of Clinical Oncology; BCCA
= British Columbia Cancer Agency; CALGB = Cancer and
Leukaemia Group B; CEPP = cyclophosphamide, etopos-
ide, procarbazine and prednisone; CHOEP = cyclophosph-
amide, doxorubicin, vincristine, etoposide and prednisone;
CHOP = cyclophosphamide, doxorubicin, vincristine and
prednisone; CNS = central nervous system; CORAL =
Collaborative Trial in Relapsed Aggressive Lymphoma;
CR = complete response; CT = computerised tomography;
DFS = disease-free survival; DLBCL = diffuse large B-
cell lymphoma; DSHNHL = German High-Grade Non-
Hodgkin's Lymphoma Study Group; EFS = event-free sur-
vival; EORTC = European Organization for Research and
Treatment of Cancer; ESHAP = etoposide, solumedrol,
high-dose cytarabine and platinum; EPOCH = etoposide,
prednisone, vincristine, cyclophosphamide and doxorubi-
cin; ESMO = European Society for Medical Oncology; FIL
= Italian Lymphoma Foundation; FISH = fluorescence in-
situ hybridisation; GCB = germinal centre B-cell – like;
G-CSF = granulocyte colony-stimulating factor; GELA =
Groupe d'Etude des Lymphomes de l'Adulte; HDT = high
dose therapy; HIV = human immunodeficiency virus; ICE
= ifosfamide, carboplatin and etoposide; IFRT = involved-
field radiation therapy; IPI = International Prognostic In-
dex; LDH = lactate dehydrogenase; MInT = MabThera
International Trial; NCCN = National Comprehensive Can-
cer Network; NHL = Non-Hodgkin’s lymphoma; NOS =
not otherwise specified; OS = overall survival; PET =
positron emission tomography; PMBL = primary medi-
astinal B-cell lymphoma; PFS = progression-free survival;
R = rituximab; RICOVER-60 = Rituximab with CHOP
over age 60 years; SCT = stem cell transplantation; SAKK
= Schweizerische Arbeitsgruppe für Klinische
Krebsforschung; SWOG = Southwest Oncology Group;
WHO = World Health Organisation.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
frequently-occurring lymphoma, accounting for an estim-
ated 35% of all lymphoma cases worldwide. In the Western
world, nearly 90% of aggressive mature B-cell lymphomas
are identified as DLBCL. This heterogeneous disease has
a complex classification, and if left untreated, takes an ag-
gressive and fatal clinical course. Patients typically present
with nodal or extranodal disease, usually exhibiting rapid
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tumour growth and symptoms that are highly dependent
upon the tumour localisation.
For over 25 years, the CHOP (cyclophosphamide, doxor-
ubicin, vincristine and prednisone) regimen was the gold
standard for the treatment of DLBCL. Today, the addition
of monoclonal antibodies such as rituximab (R) has altered
the therapeutic landscape and improved clinical outcomes.
However, despite recent advances in the classification and
molecular profiling of the disease, its biological hetero-
geneity still hampers diagnosis, prognosis and treatment.
Compounding this challenge, more than half of the patients
diagnosed with DLBCL are over 60 years of age. Thus,
today’s clinician has to walk the line between efficacy and
tolerability for a disease in which many issues remain to
be resolved with respect to aetiology, pathology and treat-
ment.
The present review aims to discuss some of the key issues
that affect clinical practice with respect to the diagnosis,
treatment, and follow-up of DLBCL patients.
Diagnosis and staging
B-cell lymphomas are malignant cellular proliferations that
arise at various steps during the process of normal B-cell
Figure 1
Typical morphological appearance of DLBCL.
Figure 2
C-MYC gene rearrangement, demonstrated by a “break-apart”
FISH probe. Note free green and red signals corresponding to the
rearranged allele as well as fused signals corresponding to the
second non-rearranged allele.
development occurring in the primary lymphoid organs and
secondary lymphoid tissues or at various non-lymphoid
sites [1]. DLBCL is a large B lymphoid cell neoplasm with
a diffuse growth pattern composed of large B-lymphocytes
with nuclear size equal to or exceeding normal macro-
phage nuclei or more than twice the size of normal lymph-
ocytes (fig. 1). Morphological, biological and clinical stud-
ies have identified distinct morphological variants, molecu-
lar and phenotypic subgroups and clinico-pathological en-
tities amongst DLBCL [2]. Yet, most DLBCL cases would
be finally classified as DLBCL not otherwise specified
(NOS), not meeting the classification criteria of a specific
subtype as proposed by the current World Health Organisa-
tion (WHO) system of classification [2].
The WHO divides DLBCL into subtypes based on clinical,
morphological, immunological and genetic features (table
1) [3, 4]. There are three main morphologic variants each
with its own characteristic cytological parameters: centro-
blastic, immunoblastic and anaplastic, with the immuno-
blastic variant being associated with the worst prognosis
[5]. Unfortunately, the identification of immunoblastic
variants is often not reproducible [2]. Phenotypically, over
95% of DLBCL cases express pan-B-cell markers, such as
CD20 [6]; a few phenotypic markers such as FoxP1 and
Cyclin E are consistently associated with poor outcome [7].
The prognostic value of Bcl-2 expression has been abol-
ished by the incorporation of rituximab into standard thera-
peutic regimens [8].
DLBCL probably arises via a stepwise process of somatic
mutations, particularly chromosomal translocations in-
volving oncogenes and, often, promoter regions of the im-
munoglobulin genes. The genes most commonly rear-
ranged in DLBCL are BCL6 (over 30% of cases), BCL2
(approximately 20% of cases) and C-MYC (5–10% of
cases). Somatic point mutations in other genes including
CARD11, A20 and TNFRSF11A leading to NF-κB pathway
activation are also observed in 10 to 20% of cases [9]. Ex-
cept for rearrangements of C-MYC, all other recurrent ge-
netic abnormalities in DLBCL have not yet been linked to
a specific outcome. DLBCL with C-MYC rearrangements
(fig. 2) has a poorer prognosis and is poorly responsive
even to rituximab plus CHOP (R-CHOP) therapy, with ap-
proximately 50% of patients showing early relapses or pro-
gressive disease [10–12].
Gene expression profiling divides DLBCL into three mo-
lecular subtypes, germinal centre B-cell – like (GCB)
DLBCL, activated B-cell – like (ABC) DLBCL and
primary mediastinal B-cell lymphoma (PMBL). The GCB-
like cases are associated with better prognosis and respond
well to etoposide and rituximab [13], whereas ABC-like
cases have a poorer prognosis but could benefit from the
addition of bortezomib [14] and rituximab [15] to a CHOP-
like regimen. Nevertheless, gene expression data do not
capture all the biological parameters that influence dia-
gnosis and response to therapy. Attempts at phenotypic
stratification of DLBCL have failed to reliably classify the
disease into GCB and ABC subtypes [16], leaving gene-
profiling as the current gold standard.
The clinical variables with prognostic significance in
DLBCL such as age, disease stage, serum lactate dehyd-
rogenase (LDH) levels, performance status and extranodal
Review article Swiss Med Wkly. 2012;142:w13511
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involvement form the basis of the International Prognostic
Index (IPI) (table 2). The IPI has prognostic value inde-
pendent of molecular subtyping. Due to the importance of
age in determining treatment and outcome, the age-adjus-
ted IPI (aaIPI; table 2) is widely used in the management of
elderly DLBCL patients, and includes only three of these
prognostic factors (performance status, disease stage and
LDH level) [17].
Currently, the only reliable diagnosis of DLBCL is ob-
tained through tissue-based histopathological examination.
Whenever possible, excisional biopsies are preferred over
core needle biopsies in order to ensure sufficient tissue
for morphological and molecular analysis [18]. The current
ESMO guidelines also highlight the importance of obtain-
ing enough material [19]. Once diagnosis has been es-
tablished, the patient undergoes staging, which involves
medical history, physical examination and blood chemistry
testing including LDH and uric acid. Screening for HIV,
Hepatitis B and C as well as protein electrophoresis are also
recommended. In case of positivity for hepatitis B surface
antigen (HBsAg) or antibodies to hepatitis B core antigen
(anti-HBc), prophylactic treatment with an antiviral drug
needs to be considered during and several months after
treatment with immunochemotherapy regimens containing
a B-cell-specific antibody, because of potentially fatal hep-
atitis reactivation [20].
Imaging techniques routinely used for staging prior to ther-
apy include contrast-enhanced computed tomography (CT)
and 18F-fluorodeoxyglucose positron emission tomography
(18FDG-PET) scanning. ESMO guidelines suggest at least
a CT scan of the chest and abdomen in patients eligible
for curative therapy [19, 21], while giving a strong recom-
mendation for the use of PET scanning to better delineate
the extent of the disease [22].
The role of 18FDG-PET in DLBCL
The use of interim PET/CT scanning is currently the focus
of many clinical trials in DLBCL. The prognostic and pre-
dictive value of this procedure may be assessed at various
timepoints: at initial diagnosis, after two to four treatment
cycles (interim PET/CT), at the end of treatment, in the fol-
low up phase, at the time of relapse, after the induction
of salvage treatment and after salvage high-dose therapy.
PET/CTs are performed not only to improve diagnostic ac-
curacy but are increasingly used to guide treatment de-
cisions. Along with Hodgkin’s lymphoma, DLBCL be-
longs to the group of the intensely 18FDG-PET “avid” tu-
mours [23]. Although the procedure results in upstaging
of about 10–20% of the cases at initial diagnosis, this fact
rarely alters the choice of treatment. Consequently, an ini-
tial PET/CT may not be absolutely necessary. However, the
use of PET/CT scanning for initial staging of DLBCL is
strongly recommended in current clinical guidelines [24].
In addition, since interim or later PET/CTs may become
more important, nuclear medicine specialists place em-
phasis on the fact that images taken at initial diagnosis are
mandatory or at least helpful to reliably assess PET images
taken during or at the end of treatment.
The role of interim PET/CT scanning to monitor response
during therapy is currently one of the most debated ques-
tions in clinical trials and has led to conflicting results
[25–31]. This question was also addressed in a trial run
by the Schweizerische Arbeitsgruppe für Klinische
Krebsforschung (SAKK; trial 38/07). Interim results of this
trial have been recently published [32]. Although a negat-
ive interim PET is strongly associated with a durable com-
plete response, a positive PET after only two or four cycles
of R-CHOP14 cannot reliably predict outcome [32]. At
present, the use of interim (mid-treatment) PET/CT scan-
ning for response assessment in DLBCL is only recom-
mended within clinical trials [24, 33, 34].
In current daily practice, PET/CT scanning has its clearest
role in restaging patients at the end of treatment. In this set-
ting, PET/CT scanning has a high negative predictive value
(between 85% to over 90%) in patients with Hodgkin’s
lymphoma or DLBCL. Data from the Vancouver lymph-
oma group have suggested that in patients with residual ab-
normalities ≥2 cm on conventional CT scan, PET/CT may
help to select individuals who need consolidative radiation
after the end of chemotherapy [35]. Studies are also un-
derway to evaluate PET/CT scanning after the induction of
salvage treatment to decide whether the use of autologous
or allogeneic stem cell transplantation is more appropriate.
In conclusion, PET/CT scanning in DLBCL has been
shown to be most useful at the time of initial staging and at
the end of primary treatment, whereas the value of interim
PET scanning to monitor response and guide treatment de-
cisions is much less clear. In the setting of relapsed disease,
PET/CT scanning may be helpful in guiding treatment ap-
proaches; however, more data are needed in order to gener-
ate reliable treatment algorithms.
First-line treatment
If left untreated, DLBCL has a median survival of less
than 1 year [36]. Prior to the rituximab era, anthracycline-
based chemotherapy regimens alongside involved-field ra-
diation formed the basis of treatment [37, 38]. The intro-
duction of the chimaeric monoclonal anti-CD20 antibody
rituximab a decade ago was a milestone in the treatment
of B-cell lymphomas including DLBCL, greatly improving
progression-free survival (PFS) and overall survival (OS)
[39–41].
Elderly patients (60-80 years)
In general, patients over 60 years are classified as elderly;
this population comprises over half of those diagnosed with
aggressive disease [42]. The original data illustrating the
benefits of R-CHOP therapy was established in elderly pa-
tients. Based on the results of earlier Phase II trials in pa-
tients with indolent and aggressive lymphomas, the Groupe
d’Etudes des Lymphomes de l’Adulte (GELA) conducted
a study comparing eight cycles of R-CHOP against eight
cycles of CHOP alone administered every 21 days in pa-
tients over 60 years of age. R-CHOP21 resulted in signi-
ficantly higher complete response rates (76% vs. 63% for
CHOP alone; P = 0.0005) and two-year OS rates (70% vs.
57% for CHOP alone; P = 0.007) [43]. These findings have
been confirmed in the five- and ten-year follow-up res-
ults, which showed statistically-significant benefits in fa-
vour of R-CHOP in terms of PFS, OS, event-free survival
(EFS) and disease-free survival (DFS); (P = 0.00001, P
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Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 15
= 0.0073, P = 0.00002, P = 0.00031, respectively) [44,
45]. The GELA findings were corroborated independently
in the E4494 study run by the US Intergroup [46].
The results from the RICOVER-60 trial have added new in-
formation on the R-CHOP dosing schedule [47]. The trial
was based on a bifactorial design comparing six versus
eight cycles of CHOP14 with or without eight cycles of
rituximab in patients between 60–80 years of age. All pa-
tients received recombinant granulocyte colony-stimulat-
ing factor (G-CSF) support. The findings reported by Pfre-
undschuh et al. suggest that a dose-dense treatment sched-
ule may improve outcomes, particularly in patients with
poor prognosis. Six cycles of R-CHOP14 followed by two
cycles of rituximab (6xR-CHOP14 + 2R) significantly im-
proved EFS, PFS and OS compared to six cycles of
CHOP14; extending chemotherapy to eight cycles con-
ferred no additional clinical benefits. An important aspect
of the RICOVER-60 trial was the high compliance to the
dosing regimen (≥98% and ≥95% median relative dose for
the six- and eight-cycle regimens, respectively). The in-
troduction of pre-phase treatment (1 mg vincristine once
and 100 mg prednisone daily around 1 week prior to the
first CHOP cycle) has greatly minimised the first-cycle ef-
fect and tumour lysis syndrome, allowing for the successful
completion of therapy in most patients [47, 48].
Although the RICOVER-60 trial was based on a dose-
dense R-CHOP regimen, the superiority of R-CHOP14
versus the standard R-CHOP21 regimen still lacks formal
clinical validation. Surprisingly, data from a trial by the
UK NCRI do not indicate the superiority of dose-dense R-
CHOP [49, 50]. Results from this trial showed no differen-
ces in either complete or overall response rates, or failure-
free and overall survival. Of note, this trial was not restric-
ted to patients between 60–80 years of age; around half
of the patient cohort were younger patients between 18–60
years of age. Similarly, the recently presented second inter-
im analysis of the LNH03-6B trial did not support the hy-
pothesis of the higher efficacy of dose dense R-CHOP14
over R-CHOP21 with respect to EFS, PFS and OS [51].
Long-term follow up is needed before establishing a pre-
ferred dosing regimen. For the time being, both R-CHOP14
and R-CHOP21 will remain in the front line as standard-of-
care therapies for patients above 60 years of age.
Table 1: DLBCL variants, subgroups and subtypes (from Jaffe et al. [116]).
DLBCL, not otherwise specified
Common morphologic variants:
Centroblastic
Immunoblastic
Anaplastic
Rare morphologic variants
Molecular subgroups
GCB
ABC
Primary mediastinal large cell lymphoma
Immunohistochemical subgroups
CD5-positive DLBCL
GCB-like
non-GCB – like
DLBCL subtypes
T-cell/histiocyte-rich large B-cell lymphoma
Primary DLBCL of the CNS
Primary cutaneous DLBCL, leg type
EBV-positive DLBCL of the elderly
Other lymphomas of large B-cells
Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
DLBCL associated with chronic inflammation
Lymphomatoid granulomatosis
ALK-positive LBCL
Plasmablastic lymphoma
Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease
Primary effusion lymphoma
Table 2: The International Prognostic Index (IPI) [117] and age-adjusted IPI [118] for Non-Hodgkin’s Lymphoma.
Risk Factor 0 Point 1 Point
IPI
Age ≤60 years >60 years
Ann Arbor stage I or II III or IV
Serum LDH level Normal Above normal
Number of extranodal sites of involvement ≤1 >1
ECOG performance status 0–1 ≥2
aaIPI (≤60 years or >60 years)
Ann Arbor stage I or II III or IV
Serum LDH level Normal Above normal
ECOG performance status ≤1 >1
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Several lines of evidence suggest that there is potential for
improving clinical outcomes by further exploiting ritux-
imab dosing. First, pharmacokinetic data from the
RICOVER-60 trial showed that rituximab trough serum
levels increased slowly and only reached a plateau after
the fifth or sixth administration. The DENSE-R-CHOP14
trial explored the effect of four additional rituximab ap-
plications during the first 3 weeks to the standard regimen
of eight rituximab and six CHOP14 cycles (for a total of
12 applications of rituximab). Preliminary data from this
study suggest higher immediate rituximab serum levels and
higher complete response rates [52]. However, these results
have not been fully published yet and will need to be con-
firmed by independent data. Gender appears to matter in
the treatment of DLBCL patients with male patients having
lower rituximab trough serum levels and poorer three-year
PFS (relative risk for progression 1.6; P = 0.004) compared
to female patients. This question is being investigated in
the ongoing DENSE-R-UP-CHOP14 study in which fe-
male patients receive 375 mg/m2 and male patients receive
500 mg/m2 [53].
Very elderly patients (>80 years)
The majority of clinical trials on elderly DLBCL patients
have excluded patients over 80 years of age. Due to the lack
of data, treatment of this group of very old patients is con-
troversial [54]. In a retrospective analysis of patients over
80 years of age, Italiano et al. showed that the addition of
rituximab to reduced-dose CHOP chemotherapy provides a
good compromise between toxicity and efficacy [55]. Res-
ults from one of the first prospective studies in patients
over 80 years of age combining rituximab with a dose-re-
duced CHOP regimen (R-miniCHOP) showed promising
clinical response and two-year OS rates of 59% [56]. The
only factor influencing OS was a serum albumin concen-
tration of ≤35 g/L (hazard ratio 3.2, 95% CI 1.4–7.1; P =
0.0053). The good tolerability profile allowed the majority
of patients to complete the planned treatment and supports
the application of a dose-reduced chemotherapy regimen in
the very elderly. The potential for achieving disease cure is
still a valid option for this patient subgroup, encouraging
clinicians to consider an R-CHOP – based regimen in eld-
erly patients with good performance status. For elderly pa-
tients not eligible to receive R-CHOP therapy, exploratory
studies on alternate chemotherapy partners (such as benda-
mustine) for rituximab have also showed promising results,
though these need to be confirmed in larger numbers of pa-
tients [57].
Young patients (18–60 years)
The treatment of younger patients with DLBCL is gener-
ally stratified according to disease risk assessed by aaIPI
score. In patients with no more than one risk factor accord-
ing to the aaIPI, six to eight cycles of R-CHOP21 is cur-
rently the mainstay of most treatment regimens [19, 58]. In
practice, many oncologists have begun using R-CHOP14
– based treatment regimens, analogous to that used in the
RICOVER-60 trial. There is no evidence that the therapeut-
ic index of this regimen is inferior to that of R-CHOP21,
and furthermore the use of R-CHOP14 offers the patient
a substantially shorter time on treatment (three vs. five
months).
Young, low-risk patients
The MInT trial was one of the first studies to demonstrate
the benefits of rituximab plus CHOP chemotherapy over
chemotherapy alone. In this study, a total of 824 patients
aged 18–60 years with 0–1 risk factors according to the
aaIPI were randomised to six cycles of CHOP or CHOP-
like chemotherapy, either with or without rituximab fol-
lowed by radiotherapy to bulky and extranodal sites [59].
A key finding was that the incorporation of rituximab con-
ferred significant survival benefits with respect to EFS as
well as OS compared to chemotherapy alone in younger
good-prognosis patients with newly diagnosed DLBCL.
In a recent update, the improvement in PFS (79.9% vs.
63.8%; P <0.0001) and OS (89.8% vs. 80%; P = 0.001)
for immunochemotherapy was maintained after a median
follow-up of 70 months [60]. Multivariate analysis demon-
strated that EFS, PFS and OS were affected not only by
the addition of rituximab, but also by aaIPI score and the
presence of bulky disease. Consequently, two subgroups
amongst younger patients with good prognosis could be
distinguished: those with a very favourable prognosis
(aaIPI = 0 with no bulky disease) and a less favourable sub-
group (aaIPI = 1 and/or bulky disease) [60]. Based on these
results, the ongoing FLYER study (DSHNHL-2004-2) run
by the German High-Grade Non-Hodgkin’s Lymphoma
Study Group (DSHNHL) will test the feasibility of a dose
reduction (by comparing four versus six cycles of
CHOP-21 chemotherapy with six applications of rituximab
in each treatment arm) in the subgroup of young patients
with very favourable prognosis with the aim of reducing
toxicity without compromising efficacy. Results from this
trial will be complemented by the UNFOLDER study
(DSHNHL-2004-3) investigating whether dose-dense ap-
plication of the R-CHOP regimen every two weeks has im-
proved efficacy compared to the standard R-CHOP-21 re-
gimen in the less favourable prognosis subgroup.
The LNH03-2B study conducted by the GELA explored
the combination of eight cycles of rituximab with an intens-
ive ACVBP (doxorubicin, cyclophosphamide, vincristine,
bleomycin and prednisone) regimen against a standard arm
with eight cycles of R-CHOP21 in younger DLBCL pa-
tients with an aaIPI of 1. The rationale for this study was
based on previously published findings demonstrating the
superiority of ACVBP over CHOP21 alone in patients with
DLBCL in the pre-rituximab era [61, 62]. Compared to
patients in the R-CHOP21 arm, patients treated with R-
ACVBP had significantly improved three-year EFS (80.9%
vs. 66.7%, p = 0.0035), PFS (86.8% vs. 73.4%, p = 0.0015)
and OS (92.2% vs. 83.8%, p = 0.0071) [63]. However,
the ACVBP regimen was associated with more treatment-
related toxicities, particularly Grade 3–4 haematological
events. Long-term follow-up results from this study are
needed before the risk-benefits of R-ACVBP versus R-
CHOP can be properly assessed. Although no direct com-
parison between the results of this trial and the previously
mentioned MInT trial can be made, it is nonetheless inter-
esting to note that the outcome of the corresponding sub-
group of patients with 1 risk factor in the MInT trial treated
Review article Swiss Med Wkly. 2012;142:w13511
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with only six cycles of R-CHOP21 appears to be similar
to the more intensively-treated subgroup in the R-ACVBP
arm and even superior to the standard arm with eight cycles
of R-CHOP in the GELA study. The fact that only patients
in the MInT trial received radiotherapy for bulky or ex-
tranodal disease – whereas no radiotherapy was planned in
the GELA trial – raises the question on the value of ra-
diotherapy after the full course of immunochemotherapy in
DLBCL patients. The eagerly awaited UNFOLDER trial
will address the role of consolidative radiotherapy in this
setting.
Young, high-risk patients
Although it has not been formally validated, the combina-
tion of rituximab plus CHOP is accepted as the benchmark
against which new dosing regimens or agents are measured
[64, 65]. There is currently no consensus on the optimal
treatment for younger patients with unfavourable aaIPI
scores (aaIPI 2-3) and the best option for these patients is
to enrol them in well-designed clinical trials. Intensified
variants to the CHOP regimen have been tested, including
the addition of etoposide (CHOEP21: 100 mg/m2 on days
1–3), and the use of recombinant human G-CSF alongside
dose-dense CHOP14 or CHOEP14 [66]. Notably, the addi-
tion of rituximab to CHOEP or CHOP equalised the benefit
of etoposide in a young, good-prognosis patient population
[59]. However, in a recent population-based investigation
from the Danish Lymphoma Group, the R-CHOEP14 re-
gimen compared favourably with the R-CHOP14 regimen
(without etoposide) in young high-risk patients with 2–3
risk factors according to the aaIPI (4-year OS 75% vs. 62%,
p = 0.04, respectively) [67]. To assess the clinical outcome
and influence of various biomarkers in a group of patients
treated with dose-adjusted R-EPOCH, the CALGB is in-
vestigating germinal centre B-cell (GCB) and post-GCB
subtypes by immunohistochemistry [13]. The combination
of R-CHOP with bortezomib is being tested in those with
the ABC subtype [14]. Dose-adjusted R-EPOCH was
shown to overcome the negative prognostic value of trans-
located C-MYC [68]. Other dose-intensive regimens are be-
ing explored, including R-ACVBP [69, 70].
One of the most extensively debated issues in this context
is the role of up-front high dose chemotherapy (HDT) fol-
lowed by autologous stem cell transplantation (ASCT) for
younger patients with high risk disease. A meta-analysis
of 15 randomised controlled trials failed to demonstrate
a clear benefit for HDT with ASCT as first-line therapy
[71]. Recently, the results of four additional randomised
trials incorporating rituximab have been presented. In the
GOELAMS075 trial, eight cycles of R-CHOP14 resulted in
a similar three-year PFS/DFS compared to rituximab plus
HDT (76% vs. 83% respectively, for both treatment arms)
but R-CHOP14 was better tolerated [72]. Similarly, HDT
with R-MegaCHOEP14 followed by ASCT was no more
effective than eight cycles of R-CHOEP14 but was asso-
ciated with a much higher incidence of infections in the
DSHNHL Phase III trial in young high-risk DLBCL pa-
tients with 2–3 risk factors according to the aaIPI [73].
The two-year PFS results were similar in both arms, with
even superior results for the R-CHOEP14 regimen in the
subgroup of patients with only 2 risk factors according to
the aaIPI. Overall, the R-CHOEP14 regimen resulted in an
excellent PFS (73.7%) and OS (84.6%) in this poor-pro-
gnosis population. On the basis of these encouraging res-
ults, the DSHNHL is currently investigating whether op-
timized rituximab administration can further improve the
outcomes of the R-CHOEP14 regimen. In contrast, HDT
followed by ASCT after four cycles of R-CHOP14 or R-
MegaCHOP14 (R-HDC + ASCT) resulted in a superior
two-year PFS compared to the pooled population of stand-
ard R-CHOP14 or R-MegaCHOP14 in the DLCL04 tri-
al conducted by the FIL [74]. So far, this advantage in
PFS has not been translated into an OS benefit and longer
follow-up will be needed to clarify the role of HDT in this
setting. It is noteworthy that the two-year PFS curves in
both the non-ASCT arms were superimposable, showing
similar results for eight cycles of R-CHOP14 and six cycles
of the investigational dose-intensified R-MegaCHOP14 re-
gimen. Finally, the results of a U.S./Canadian Intergroup
trial (SWOG S9704) have recently been presented [75].
After induction therapy with five cycles of CHOP21 (±
rituximab), 253 of 397 enrolled patients were randomly as-
signed to either three additional cycles of CHOP (± ritux-
imab) or one additional cycle of CHOP (± rituximab) fol-
lowed by HDT with ASCT. Two-year PFS was 69 and
56%, respectively [hazard ratio: 1.72; 95% CI: 1.18-2.51;
p = 0.005] in favour of HDT over conventional therapy.
However, there was no difference in OS between the treat-
ment arms (71% versus 74%, respectively, p = 0.32). Ex-
ploratory analysis indicated that the majority of clinical
benefits occurred in the high risk group (aaIPI = 3). Never-
theless, these conclusions should be interpreted with cau-
tion as only 44 patients in each treatment arm belonged to
the latter group.
Taken together, these clinical data do not unequivocally
demonstrate the superiority of consolidation therapy with
HDT and ASCT as first-line therapy over six to eight
cycles of CHO(E)P-like chemotherapy combined with
eight doses of rituximab. In accordance with the current
ESMO guidelines, these new regimens remain experiment-
al. It is highly recommended that young patients with poor
prognosis are treated within a clinical trial [19].
Abbreviated therapies
In patients with “limited disease” (usually defined as stage
I and non-bulky stage II disease), the use of abbreviated
chemotherapy followed by involved-field radiation therapy
(IFRT) has been the subject of clinical trials [76]. The ad-
vantages of this abbreviated regimen are thought to be 1)
decreased risk of cardiotoxic effects due to the lower total
dose of doxorubicin, 2) the use of two treatments without
cross-resistance, and 3) the direct application of radiother-
apy to sites of disease [77]. The SWOG initially demon-
strated that three cycles of CHOP followed by IFRT was
superior to eight cycles of CHOP in patients with local-
ized DLBCL in terms of five-year PFS and OS (77% vs.
64%, P = 0.03; and 82% vs. 72%, P = 0.02, respectively)
[77]. However, the initial superiority of the combined ap-
proach disappeared with longer follow-up [78], indicating
that the shorter duration of therapy may be associated with
higher relapse rates [58]. A later study conducted by the
SWOG showed that the addition of four cycles of rituxim-
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ab to abbreviated CHOP in combination with IFRT resulted
in even higher PFS and OS rates than CHOP alone (PFS:
93% at 2 years and 88% at 4 years; OS: 95% at 2 years
and 92% at 4 years) [79]. However, in this trial a continu-
ing pattern of relapse without a plateau in either the PFS
or OS curves was noted, suggesting that the abbreviated
immunochemotherapy regimen may have failed to eradic-
ate the malignant clone. Another hypothesis raised is that
limited-stage DLBCL may be a separate molecular entity
from advanced-stage disease, warranting further investiga-
tion into specific treatment regimens for this subgroup of
patients [79, 80].
Recently, Sehn et al. presented data from 134 patients with
non-bulky, limited stage I and II disease using a PET-based
approach to tailor therapy: patients with a negative PET
scan (n = 103) following three cycles of R-CHOP received
only one additional cycle of R-CHOP, whereas PET-pos-
itive patients received IFRT. After a median follow-up of
30 months, seven of 103 patients have relapsed and the
three-year OS was 96%. However, in the group of patients
with a positive PET scan after three cycles of R-CHOP,
treatment with IFRT was unsatisfactory with high (9/30 pa-
tients) distant relapse rates [81]. The results from this pub-
lication suggest that in those with localized disease, PET
scanning might aid in identifying patients who may benefit
from abbreviated chemotherapy. However, the appropriate
treatment for patients with a positive PET scan after im-
munochemotherapy remains to be validated.
The role of radiotherapy
There is much controversy over the benefits of radiother-
apy in the treatment of DLBCL. Radiotherapy has gener-
ally been used in combination with chemotherapy either
with or without rituximab for the treatment of patients
with localised disease. Two randomised studies showed
that consolidation RT can improve EFS and OS in patients
with stage I/II disease. The SWOG study (discussed above)
was one of the first to show the potential benefits of three
cycles of CHOP followed by IFRT in patients with stage
I or non-bulky stage II disease [77]. These results have
been supported independently in a retrospective analysis by
the British Columbia Cancer Agency (BCCA) [82]. In con-
trast, a GELA trial (93-4) in elderly patients (>60 years) did
not establish any benefits for the addition of IFRT to four
cycles of CHOP [83]. In a separate study conducted by the
GELA, ACVBP alone was shown to be superior to IFRT
plus CHOP in a group of younger patients with localised
disease [62], though this regimen has not been widely im-
plemented due to increased toxicity [84].
The conflict surrounding the use of radiotherapy is partly
a result of key unanswered questions on the biology of
DLBCL. What are the clinical definitions for “limited
stage”, “early-stage” or “localised” disease? There is cur-
rently great heterogeneity amongst the patient populations
included in these clinical trials. Patients within the stage
I-II categories have dramatically different survival out-
comes: those with stage I or IE disease respond well re-
gardless of therapeutic regimen, whereas those with bulky
(any mass >10 cm) Stage II disease resemble those with
advanced disease in terms of prognosis and treatment out-
comes [84].
The results of the MInT trial for young, good prognosis
patients offer some insight into the role of radiotherapy in
the treatment of this subgroup. The study cohort as defined
by stage, IPI risk factors and bulky disease included pa-
tients with bulky stage I or stage II–IV disease (with 0–1
aaIPI risk factors). Radiotherapy at doses of 30–40 Gray
was given to patients with bulky disease (defined as more
than 5 cm in diameter). Retrospective subgroup analysis
showed that the most favourable subset (those with no risk
factors or bulky disease) had a 90% survival without ra-
diotherapy. Bulky disease emerged as a strong independent
prognostic factor for EFS, PFS and OS, even though pa-
tients with bulky disease received additional radiotherapy
[59, 85]. A historical comparison of two DSHNHL studies
conducted in elderly patients showed no benefits of addi-
tional radiotherapy in patients with bulky disease who had
already achieved complete response after six cycles of R-
CHOP14. However, radiotherapy may be beneficial in eld-
erly patients with bulky disease achieving only a partial
remission after completion of immunochemotherapy [86].
As discussed in the previous section, the superiority of the
MInT trial results (where patients with bulky disease re-
ceived radiotherapy) against those of the LNH03-2B trial
(no radiotherapy used) continues to fuel the radiotherapy
debate. The UNFOLDER study will provide further insight
into the role of consolidative radiotherapy for bulky and/or
extranodal disease.
Additional efforts are underway exploring the use of PET
scanning to focus radiation therapy on PET-positive resid-
ual masses. Recently, Sehn et al. reported on a series of
196 patients with advanced-stage disease who had residual
abnormalities >2 cm on end-of-treatment CT scans after
6–8 cycles of R-CHOP immunochemotherapy. All patients
underwent additional PET scanning. Patients with a neg-
ative PET scan were observed (regardless of initial or re-
sidual bulk), while patients with a positive PET scan re-
ceived consolidative radiation therapy to the PET-positive
sites: this resulted in an outcome similar to those with a
negative PET upon completion of R-CHOP therapy [35].
This observation suggests a role for PET-guided consolid-
ative radiotherapy for patients with residual masses on end-
of-treatment imaging following immunochemotherapy.
Treatment of relapsed disease
Despite the improved efficacy of first-line treatment regi-
mens, a significant proportion of patients experience dis-
ease progression or relapse. The outlook for this subgroup
is dismal, with a median survival time of 6 months or less
[87, 88]. The standard approach to relapsing DLBCL is
high-dose therapy and autologous stem cell transplantation
(SCT). Prior to the rituximab era, results from the PARMA
trial demonstrated improved event-free survival (EFS) and
OS in chemosensitive patients who received a platinum and
cytarabine-based chemotherapy regimen (DHAP) in com-
bination with autologous SCT, compared to those who re-
ceived DHAP treatment alone [89, 90]. Since then, addi-
tional salvage regimens have been explored either alone
or with the use of rituximab, including ESHAP [91, 92]
EPOCH [93], CEPP [94, 95] and ICE [96, 97].
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The clinical impact of relapsing disease has been re-eval-
uated in the rituximab era. The high efficacy of R-CHOP
as a first-line therapy has led to a smaller proportion of re-
lapses, but those who relapse present a significant clinical
challenge. The choice of salvage therapy in patients who
failed first-line therapy was explored in the Phase III
CORAL trial [98]. A total of 396 relapsing DLBCL pa-
tients were randomised to receive three courses of either
R-ICE or R-DHAP salvage therapy; responders were given
HDT and autologous SCT. No significant differences were
seen between R-ICE and R-DHAP in terms of overall re-
sponse rates, three-year PFS and OS. Multivariate analysis
revealed three main factors that influenced OS: second-
line aaIPI ≥2, relapse occurring <12 months after first-line
treatment, and prior rituximab exposure. Interestingly, the
retrospective evaluation of the prognostic value of the cell
of origin using the Hans algorithm revealed that patients
with GCB-like DLBCL had an improved outcome with re-
gards to PFS and OS when treated with R-DHAP compared
with R-ICE. The independent prognostic impact of the cell
of origin interaction with treatment was confirmed in mul-
tivariate analysis. These results demonstrate that the cell of
origin is an important predictive factor for the response to
non-anthracycline-based immunochemotherapy salvage re-
gimens in patients with relapsed/ refractory DLBCL [99].
The poor results of standard high dose therapy (HDT) plus
autologous SCT – particularly for rituximab-pretreated pa-
tients with only about 20% achieving long-term second
remissions [98] – underscore the need for new treatment
strategies for patients who relapse after front-line and sal-
vage rituximab-containing therapy. A plethora of new
therapeutic agents targeting the various pathways linked to
the pathogenesis of DLBCL are currently under investiga-
tion [100]. However, detailed discussion of these is beyond
the scope of this review.
Allogeneic SCT is being explored as an alternative in the
subset of patients who relapse after first-line therapy and
who do not respond to salvage regimens. In general, this
treatment is reserved only for patients with poor prognosis,
refractory disease, or who have failed autologous SCT
[101]. Although some studies have shown lower relapse
rates and better survival outcomes for allogeneic compared
to autologous SCT, the high treatment-related mortality
underlies the reluctance of clinicians to recommend this
for all but a small subset of patients [102]. Recently, the
use of reduced-intensity conditioning regimens has shown
promising results [103, 104], but the optimal dosing sched-
ules remain to be defined. A French study in 68 patients
who had failed two therapeutic regimens prior to undergo-
ing reduced-intensity conditioning followed by allogeneic
SCT yielded two-year OS, PFS and relapse rates of 49%,
44% and 41%, respectively [105]. Interestingly, multivari-
ate analysis revealed that prior anti-CD20 therapy did not
affect the incidence of disease progression or relapse fol-
lowing the transplant. Allogeneic SCT is associated with
a graft-versus-lymphoma effect that could reduce the
chances of post-transplantation relapse [88], but the final
outcome is heavily dependent upon tumour histology
[106]. Thus, the question of optimal patient selection based
on disease characteristics is a major barrier to establishing
the efficacy of allogeneic SCT and the appropriate condi-
tioning regimens.
Relapsing patients who are not eligible for transplant pose a
significant clinical challenge, as few treatment options are
available. Currently, several alternative salvage regimens
are being explored. The use of six to eight cycles of ritux-
imab in combination with gemcitabine-based regimens has
shown encouraging results [107, 108]. However, the same
patterns emerge, with non-responders faring poorly (OS for
relapsed elderly patients <1 year). Similar to the situation
in post-transplant survival, the degree of chemosensitivity
is the primary factor dictating clinical outcomes following
salvage therapy. In the rituximab era, patients experiencing
relapse likely harbour disease with a distinct molecular sig-
nature requiring novel therapeutic agents. Patients falling
into this category are recommended to receive treatment
within a clinical trial.
CNS prophylaxis
Secondary involvement of the central nervous system
(CNS) in DLBCL is an infrequent event with usually fatal
consequences. The incidence is between 4–8% [109–111].
Evaluation of the cerebrospinal fluid by flow cytometry
combined with conventional cytology greatly increases the
rate of detection of clinically occult leptomeningeal dis-
ease, compared to assessment by conventional cytology
only [112]. A work-up with examination of the
cerebrospinal fluid is usually recommended in patients
with paranasal sinus, testicular, epidural, or bone marrow
involvement or if more than two extranodal sites are in-
volved.
With no effective therapies available for CNS relapse,
many experts advocate the use of prophylactic therapy for
high-risk patients. Authorities including ESMO, BCCA,
and the National Cancer Comprehensive Network (NCCN)
recommend the routine use of CNS prophylaxis in high-
risk populations [19], but there is no clear consensus on
the type of therapy. The analysis of the RICOVER-60 pa-
tient cohort suggested that intrathecal methotrexate played
no part in preventing CNS disease in patients who had been
treated with immunochemotherapy, except in patients with
testicular lymphoma [113]. More recently, the role of sys-
temic chemotherapeutic drugs able to cross the blood-brain
barrier (in particular high- or intermediate-dose methotrex-
ate) has been emphasized supported by some data from
clinical trials [114, 115]. Some studies have shown CNS
relapse rates of 2–3% in patients receiving intrathecal or
high-dose methotrexate, compared to 5–8% in those who
received only immunochemotherapy without CNS prophy-
laxis [116]. On the basis of the current data, there is a ra-
tionale favouring the use of systemic high-dose methotrex-
ate over intrathecal methotrexate for CNS prophylaxis in
high-risk patients [117]. However, the optimal prophylactic
regimen as well as more accurate predictors of CNS relapse
need to be identified before any progress can be made with
respect to the prevention of secondary CNS disease.
The widespread use of rituximab in front-line treatment re-
gimens may affect the incidence of CNS relapse. Analysis
of CNS events in the RICOVER-60 patient cohort sugges-
ted that the incorporation of rituximab to CHOP reduced
Review article Swiss Med Wkly. 2012;142:w13511
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 15
the risk of CNS involvement [113], a finding that has been
supported by some groups [118] and challenged by oth-
ers [119]. Recent data suggests that the protective effect
is most apparent in patients achieving a complete remis-
sion with R-CHOP immunochemotherapy indicating that
the beneficial effect of rituximab may be through improved
control and eradication of systemic disease [118]. Some of
the reasons for the conflicting views stem from the het-
erogeneity in the different study populations, variations in
front-line and prophylactic regimens, and a lack of agree-
ment as to which subgroup of patients should receive CNS
prophylaxis [109, 110, 120]. Consistently emerging risk
factors for CNS relapse include high IPI score, involve-
ment of more than one extranodal site, poor performance
status, elevated LDH levels, and involvement of testes, or-
bit or paranasal sinuses [113, 118, 120].
Supportive care and follow-up
During therapy, prophylaxis and treatment of systemic in-
fections are key to improving patient outcomes.
Chemotherapy-induced myelosuppression leading to
severe neutropenia greatly increases the risk of infectious
complications and might compromise the dose intensity of
the curative treatment [121]. The intensity of the chemo-
therapy regimen, presence of advanced disease, co-mor-
bidities and age are amongst the risk factors associated
with the likelihood of developing febrile neutropenia. The
American Society for Clinical Oncology (ASCO) and the
European Organisation for Research and Treatment of Can-
cer (EORTC) have included the use of G-CSF in their
guidelines for the supportive treatment of high-risk patients
[122, 123]. As febrile neutropenic events are more likely
to occur during the early cycles of chemotherapy, G-CSF
should be given early in the course of treatment [124].
The DSHNHL recommends the use of acyclovir and co-
trimoxazole [21, 47].
At the end of therapy, a complete restaging is performed.
According to ESMO guidelines and a recent review, PET
scanning is highly recommended for post-treatment assess-
ment [24]. Bone marrow aspirate and biopsy should only
be repeated at the end of treatment if initially involved.
There are no formally established guidelines on the specific
procedures recommended for response evaluation and
follow-up. In general, patient follow-up procedures are
similar after first-line as well as after relapse treatment.
ESMO guidelines recommend the patient to undergo med-
ical history and physical examinations every three months
for the first year after therapy, then every 6 months for the
following two years and once a year thereafter [19]. Al-
though repeat CT scanning at 6, 12 and 24 months after
end of treatment is common practice, there is no definitive
evidence that routine imaging for patients in complete re-
mission provides any outcome advantage [19, 121]. As the
majority of relapses occur during the first two years fol-
lowing therapy, careful clinical assessment during this time
window is critical in order to catch any signs of disease
progression.
Conclusions
The outlook for patients with DLBCL has improved, with
survival rates nearly doubling over the past ten years. The
introduction of rituximab to established chemotherapy re-
gimens such as CHOP and ACVBP was a major break-
through, allowing many patients to achieve disease cure.
The clinician, however, must continue to navigate through
the maze of new dosing regimens while balancing the pa-
tient’s clinical status alongside unresolved issues in lymph-
oma biology. There is room for improvement, particularly
in the treatment of the elderly and those with high-risk
disease. Future improvements in clinical outcomes depend
upon acquiring a greater understanding of the pathogenesis
of DLBCL. Indeed, the differing sensitivities of patients
with the same stage of lymphoma to a single treatment re-
gimen underscore the fact that there are additional para-
meters governing response to treatment not captured by our
current system of classification. New combinations of anti-
bodies with improved biological activity or new drugs that
act in concert with R-CHOP-like regimens may help to tar-
get highly malignant tumour cells that are characteristic
of high-risk disease. Additional correlations between bio-
logical parameters, therapeutic response and clinical out-
comes need to be incorporated into future clinical trials to
pave the way for biology-driven DLBCL therapy.
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Figures (large format)
Figure 1
Typical morphological appearance of DLBCL.
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Figure 2
C-MYC gene rearrangement, demonstrated by a “break-apart” FISH probe. Note free green and red signals corresponding to the rearranged
allele as well as fused signals corresponding to the second non-rearranged allele.
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